Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Description
Intravenous remdesivir (RDV) is U.S. Food and Drug Administration-approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS-443902
